These results demonstrated that the fusion HAC NVs can block CD47 and PD‐L1 checkpoints to promote phagocytosis of macrophages and tumour‐killing effect of T‐cells to trigger robust antitumour immunity in vitro. The gene discussed is CD47; the disease is neoplasm.